Filing Flows › Gilead Sciences (GILD) › R&D spending
Gilead Sciences (GILD) R&D spending by quarter
Gilead Sciences' R&D spending was $1.6B in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 7 quarters it ranged from $1.3B (Q3 2025) to $1.8B (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.6B | -9% | +19% |
| Q2 2026 | $1.8B | +29% | +18% |
| Q1 2026 | $1.4B | -13% | -0.5% |
| Q4 2025 | $1.6B | +18% | — |
| Q3 2025 | $1.3B | -10% | — |
| Q2 2025 | $1.5B | +8% | — |
| Q1 2025 | $1.4B | — | — |
Q3 2026 at a glance
Gilead Sciences, Q3 2026: revenue $8.3B (+7% year over year), operating margin 41.7%, net earnings $2.4B, operating cash flow $5.0B. The chart follows the revenue to costs, profit and cash.
Questions
What is Gilead Sciences' R&D spending?
Gilead Sciences' R&D spending was $1.6B in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has Gilead Sciences' R&D spending changed?
Over the last 7 quarters it ranged from $1.3B (Q3 2025) to $1.8B (Q2 2026).